Hologic Intrinsic Value – HOLOGIC Reports Third Quarter FY2023 Earnings Results for June 30 2023
August 20, 2023
🌥️Earnings Overview
On July 31 2023, HOLOGIC ($NASDAQ:HOLX) reported their earnings results for the third quarter of FY2023, ending on June 30 2023. Total revenue for the quarter amounted to USD 984.4 million, a slight decrease of 1.8% compared to the same quarter of the prior year. Net income for the period was reported as USD -40.5 million, in contrast to the net income of USD 228.4 million in the same quarter the year before.
Market Price
The stock opened at $80.7 and closed at $79.4, indicating a decrease of 1.6% from its previous closing price of $80.7. Due to the decrease in stock prices, analysts have expressed concern about the direction of HOLOGIC’s earnings and stock price. These plans are expected to help HOLOGIC improve its competitive edge and further solidify its position in the industry.
Overall, despite the decrease in stock price, HOLOGIC’s third quarter FY2023 earnings results show positive performance and outlook. This suggests that the company is on track to continue growing and strengthening its business, while providing long-term shareholder value. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Hologic. HOLOGIC_Reports_Third_Quarter_FY2023_Earnings_Results_for_June_30_2023″>More…
| Total Revenues | Net Income | Net Margin |
| 4.04k | 484.1 | 13.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Hologic. HOLOGIC_Reports_Third_Quarter_FY2023_Earnings_Results_for_June_30_2023″>More…
| Operations | Investing | Financing |
| 961.1 | -128.2 | -442.4 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Hologic. HOLOGIC_Reports_Third_Quarter_FY2023_Earnings_Results_for_June_30_2023″>More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 9.34k | 4.16k | 21.16 |
Key Ratios Snapshot
Some of the financial key ratios for Hologic are shown below. HOLOGIC_Reports_Third_Quarter_FY2023_Earnings_Results_for_June_30_2023″>More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 7.0% | 19.7% | 19.3% |
| FCF Margin | ROE | ROA |
| 20.6% | 9.3% | 5.2% |
Analysis – Hologic Intrinsic Value
At GoodWhale, we provide comprehensive financial analysis of HOLOGIC (HOLX). After careful research and calculations, our proprietary Valuation Line suggests that the fair value of HOLOGIC share is around $63.5. However, HOLOGIC stock is currently traded at $79.4, representing a 25.0% overvaluation compared to its fair value. We recommend investors to be cautious when considering investing in HOLOGIC. More…
Peers
The company’s products are used in a variety of settings, including hospitals, clinics, and physician offices. Hologic also provides a range of services, including support, training, and education. The company has a strong presence in the United States and international markets, and its products are backed by a large body of scientific research. ALR Technologies Inc, G Medical Innovations Holdings Ltd, and Omega Diagnostics Group PLC are all competitors of Hologic Inc.
– ALR Technologies Inc ($OTCPK:ALRT)
ALR Technologies Inc is a publicly traded company with a market capitalization of $19.32 million as of 2022. The company has a return on equity of 17.26%. ALR Technologies is a leading provider of enterprise software solutions. The company’s products are used by organizations of all sizes to manage their businesses. ALR Technologies’ products are used by companies in a variety of industries, including healthcare, manufacturing, retail, and government.
– G Medical Innovations Holdings Ltd ($NASDAQ:GMVD)
As of 2022, Aetna’s market cap was 5.58M and its ROE was 783.79%. Aetna is a diversified healthcare benefits company that offers a broad range of traditional and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioral health, group life and disability plans, and medical management capabilities and health care management services for Medicaid plans.
– Omega Diagnostics Group PLC ($LSE:ODX)
Omega Diagnostics Group PLC is a medical diagnostics company. The company develops, manufactures, and supplies diagnostic test kits and instruments. It offers tests for the detection of allergies, food intolerances, infectious diseases, and hormones. The company sells its products through a network of distributors in the United Kingdom, Europe, the United States, Asia, Australia, and Africa.
Summary
HOLOGIC had a difficult third quarter of FY2023, ending June 30, 2023, with total revenue of USD 984.4 million. This represented a 1.8% decrease compared to the same quarter last year. The company reported a net income of USD -40.5 million for the quarter, a stark contrast to a net income of USD 228.4 million during the same quarter in the prior year. As such, investors may want to take caution when considering investing in HOLOGIC, as the company’s financial performance has been weak for the past quarter.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
